Efficacy of afoxolaner (NexGard®) in preventing the transmission of Leishmania infantum and Dirofilaria immitis to sheltered dogs in a highly endemic area.
Animals
Dirofilaria immitis
/ drug effects
Dirofilariasis
/ drug therapy
Dog Diseases
/ drug therapy
Dogs
Endemic Diseases
/ veterinary
Female
Insect Vectors
/ classification
Isoxazoles
/ pharmacology
Leishmania infantum
/ drug effects
Leishmaniasis, Visceral
/ drug therapy
Mosquito Vectors
/ classification
Naphthalenes
/ pharmacology
Psychodidae
/ classification
Weather
Afoxolaner
Chemoprophylaxis
Dirofilariosis
Incidence
Insecticide
Leishmaniosis
NexGard®
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
29 Jul 2021
29 Jul 2021
Historique:
received:
05
05
2021
accepted:
20
07
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
17
12
2021
Statut:
epublish
Résumé
Leishmania infantum and Dirofilaria immitis are among the most important canine vector-borne pathogens (CVBPs) of zoonotic concern in Europe. In endemic areas for both of these CVBPs, the use of systemic ectoparasiticides, such as afoxolaner (NexGard®; Boehringer Ingelheim Animal Health), may have the potential for controlling these infections. The aim of this study was to assess, for the first time, the insecticidal efficacy of NexGard® in decreasing the transmission of D. immitis and L. infantum to sheltered dogs living in a hyperendemic area, compared to the year before treatment, as well as its impact on the abundance of mosquito and sand fly populations. All dogs (n = 179) enrolled in the study were divided into two groups based on their infection status at enrollment: a non-infected group (G1) and an infected group (G2; infected with D. immitis, L. infantum or both). The study was conducted from March 2020 to March 2021. In order to exclude all animals infected with L. infantum and D. immitis before March 2020 (sampling time: T0), dogs in G1 were sampled in June (T1; i.e. T0 + 90 days) and in October 2020 (T2; i.e. T0 + 210 days). From March to September 2020, all animals (G1 and G2) were weighed and treated monthly with NexGard®. Animals in G1 were tested for the last time in March 2021 (T3; i.e. T0 + 330 days) for assessing post-treatment incidence rate of infection and prevention efficacy. The post-treatment incidence of D. immitis was 3.7% (1/27; 95% confidence interval [CI]: 0.2-18.1) and that of L. infantum was 3.6% (3/83; 95% CI: 1.0-10.1). Considering the annual incidence in 2019 and 2020, the protective efficacy against D. immitis and L. infantum infections was 94.2 and 64%, respectively. Of the female mosquitoes collected (n = 146), only one pool out of 50 tested positive for D. immitis DNA, whereas out of 1252 female Sergentomya minuta specimens collected, only four tested positive for L. infantum (0.3%). Afoxolaner is efficacious in decreasing the rate of transmission of both D. immitis and L. infantum; however, comparison of the pre- and post-treatment period demonstrated that there was a significant difference only in the seasonal incidences of D. immitis infection. Preventive measures are recommended throughout the year in endemic areas to reduce the risk of pathogen transmission to animals and humans.
Sections du résumé
BACKGROUND
BACKGROUND
Leishmania infantum and Dirofilaria immitis are among the most important canine vector-borne pathogens (CVBPs) of zoonotic concern in Europe. In endemic areas for both of these CVBPs, the use of systemic ectoparasiticides, such as afoxolaner (NexGard®; Boehringer Ingelheim Animal Health), may have the potential for controlling these infections. The aim of this study was to assess, for the first time, the insecticidal efficacy of NexGard® in decreasing the transmission of D. immitis and L. infantum to sheltered dogs living in a hyperendemic area, compared to the year before treatment, as well as its impact on the abundance of mosquito and sand fly populations.
METHODS
METHODS
All dogs (n = 179) enrolled in the study were divided into two groups based on their infection status at enrollment: a non-infected group (G1) and an infected group (G2; infected with D. immitis, L. infantum or both). The study was conducted from March 2020 to March 2021. In order to exclude all animals infected with L. infantum and D. immitis before March 2020 (sampling time: T0), dogs in G1 were sampled in June (T1; i.e. T0 + 90 days) and in October 2020 (T2; i.e. T0 + 210 days). From March to September 2020, all animals (G1 and G2) were weighed and treated monthly with NexGard®. Animals in G1 were tested for the last time in March 2021 (T3; i.e. T0 + 330 days) for assessing post-treatment incidence rate of infection and prevention efficacy.
RESULTS
RESULTS
The post-treatment incidence of D. immitis was 3.7% (1/27; 95% confidence interval [CI]: 0.2-18.1) and that of L. infantum was 3.6% (3/83; 95% CI: 1.0-10.1). Considering the annual incidence in 2019 and 2020, the protective efficacy against D. immitis and L. infantum infections was 94.2 and 64%, respectively. Of the female mosquitoes collected (n = 146), only one pool out of 50 tested positive for D. immitis DNA, whereas out of 1252 female Sergentomya minuta specimens collected, only four tested positive for L. infantum (0.3%).
CONCLUSIONS
CONCLUSIONS
Afoxolaner is efficacious in decreasing the rate of transmission of both D. immitis and L. infantum; however, comparison of the pre- and post-treatment period demonstrated that there was a significant difference only in the seasonal incidences of D. immitis infection. Preventive measures are recommended throughout the year in endemic areas to reduce the risk of pathogen transmission to animals and humans.
Identifiants
pubmed: 34325730
doi: 10.1186/s13071-021-04883-3
pii: 10.1186/s13071-021-04883-3
pmc: PMC8323259
doi:
Substances chimiques
Isoxazoles
0
Naphthalenes
0
afoxolaner
02L07H6D0U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
381Informations de copyright
© 2021. The Author(s).
Références
Vet Parasitol. 2018 Apr 15;253:39-42
pubmed: 29605001
Trends Parasitol. 2017 Oct;33(10):813-825
pubmed: 28648798
Parasit Vectors. 2020 Apr 15;13(1):193
pubmed: 32293524
Vet Parasitol. 2007 Mar 31;144(3-4):270-8
pubmed: 17258860
Int J Parasitol. 2020 Jul;50(8):555-559
pubmed: 32479831
Trans R Soc Trop Med Hyg. 1986;80(5):771-3
pubmed: 3603616
Med Vet Entomol. 2020 Dec;34(4):470-475
pubmed: 32710462
Prev Vet Med. 1999 Apr 9;39(3):211-25
pubmed: 10327439
Parasit Vectors. 2014 Jun 23;7:283
pubmed: 24957215
Trends Parasitol. 2017 Sep;33(9):718-730
pubmed: 28601528
Parasit Vectors. 2017 Jun 23;10(1):301
pubmed: 28645329
Parasit Vectors. 2014 Oct 17;7:479
pubmed: 25323537
Vet Parasitol. 2010 Sep 20;172(3-4):323-32
pubmed: 20591573
Parasit Vectors. 2015 Mar 03;8:139
pubmed: 25886610
Acta Trop. 2010 Dec;116(3):227-34
pubmed: 20816927
Vet Parasitol. 2011 Mar 22;176(4):291-4
pubmed: 21310532
Clin Microbiol Rev. 2012 Jul;25(3):507-44
pubmed: 22763636
Parasit Vectors. 2009 Mar 26;2 Suppl 1:S2
pubmed: 19426441
Transbound Emerg Dis. 2021 Feb 6;:
pubmed: 33547868
Parasit Vectors. 2018 Apr 5;11(1):230
pubmed: 29622033
Parasit Vectors. 2014 Jul 14;7:327
pubmed: 25023573
Parasitol Res. 2021 Mar 23;:
pubmed: 33754191
Vet Parasitol Reg Stud Reports. 2017 Jan;7:48-53
pubmed: 31014657
Vet Parasitol. 2007 Nov 10;149(3-4):139-46
pubmed: 17703890
Trends Parasitol. 2012 Dec;28(12):531-8
pubmed: 22995719
J Parasitol. 2000 Apr;86(2):228-32
pubmed: 10780537
Parasite. 2019;26:63
pubmed: 31687926
Emerg Infect Dis. 2005 Feb;11(2):265-70
pubmed: 15752445
Parasit Vectors. 2012 Apr 20;5:76
pubmed: 22520170
Vet Parasitol. 2021 Feb;290:109369
pubmed: 33548595
Vet Parasitol. 2009 Aug 26;163(4):286-92
pubmed: 19398159
One Health. 2020 Aug 26;10:100159
pubmed: 33117874
Parasite. 2017;24:39
pubmed: 29063828
Clin Vaccine Immunol. 2009 Mar;16(3):337-43
pubmed: 19129471
Vet Parasitol. 2018 Feb 15;251:68-77
pubmed: 29426479
Med Vet Entomol. 2013 Jun;27(2):123-47
pubmed: 22924419
Pathogens. 2020 Jun 22;9(6):
pubmed: 32580453